Phase I Study of KN026 in HER2 Expressing Breast Cancer, Astric/Gastroesophageal Junction Cancer and Other Locally Advanced/Metastatic Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 20 Jun 2019
Price : $35 *
At a glance
- Drugs KN-026 (Primary)
- Indications Advanced breast cancer; Gastric cancer; Male breast cancer
- Focus Adverse reactions
- Sponsors Alphamab Oncology
- 18 Jun 2019 Status changed from not yet recruiting to recruiting.
- 18 Feb 2019 Status changed from planning to not yet recruiting.
- 10 Dec 2018 New trial record